Patient characteristics
| Characteristic | Arm A: cabozantinib+ nivolumab (n=36) | Arm B: nivolumab (n=18) | Arm C: cabozantinib+ nivolumab (n=23) |
| Median age, years (range) | 67 (44–77) | 66 (41–83) | 6 (53–83) |
| ECOG performance status, n (%) | |||
| 0 | 13 (36) | 10 (56) | 14 (61) |
| 1 | 19 (53) | 8 (44) | 9 (39) |
| 2 | 4 (11) | 0 | 0 |
| Histology type, n (%) | |||
| Endometrioid | 15 (42) | 5 (28) | 3 post IO (13) |
| Serous | 11 (31) + 1 unevaluable | 10 (56) + 2 unevaluable | 5 post IO (22) |
| Clear cell features | 5 (14) + 2 unevaluable | 0 | 0 |
| Mixed serous/clear cell/endometrioid | 2 (6) | 2 (11) | 1 post IO (4) |
| Adenocarcinoma | 3 (8) | 1 (6) | 3 post IO (13) |
| Carcinosarcoma | 0 | 0 | 10 + 1 post IO (48) |
| MMR status, n (%) | |||
| MMR intact | 34 (94) | 18 (100) | 18 (78) |
| MSI-high | 2 (6) | 0 | 5 post IO (22) |
| Prior treatment lines, n (%) | |||
| 2 | 19 (53) | 6 (33) | 9 (39) |
| ≥3 | 17 (47) | 12 (67) | 14 (61) |
ECOG, Eastern Cooperative Oncology Group; IO, immuno-oncology; MMR, mismatch repair system; MSI, microsatellite instability.